Clinical Characteristics of B-Cell CLL Patients
| ID No. . | Diagnosis . | Modified Rai Stage . | Previous Treatment . | Fludarabine Refractory . | Flavopiridol LC50 (4 d) . |
|---|---|---|---|---|---|
| 1a | CLL | IR | None | NA | 0.18 |
| 2a | CLL | IR | None | NA | 0.20 |
| 3a | CLL | IR | None | NA | 0.09 |
| 5a | CLL | IR | None | NA | 0.16 |
| 6a | CLL | IR | None | NA | 0.20 |
| 7a | CLL | HR | C + P, Flu, CHOP | Yes | 0.20 |
| 8a | CLL | HR | C + P, 9AC | NA | 0.24 |
| 9a | CLL | HR | C + P, Flu, DHAP | Yes | 0.20 |
| 10a | CLL | HR | C + P, Cyt, Flu | Yes | 0.09 |
| 12a | CLL | IR | None | NA | 0.02 |
| 15a | CLL | IR | C + P | NA | 0.03 |
| 16a | CLL | IR | None | NA | 0.06 |
| 17a | CLL | HR | C + P, 9AC | NA | 0.18 |
| 23a | CLL | HR | None | NA | 0.077 |
| 24a | CLL | IR | None | NA | 0.11 |
| 26a | CLL | IR | None | NA | 0.21 |
| 27a | CLL | IR | None | NA | 0.09 |
| 28a | CLL | LR | None | NA | 0.22 |
| 29a | CLL | IR | None | NA | 0.08 |
| 30a | CLL | IR | None | NA | 0.08 |
| 31a | CLL | IR | None | NA | 0.07 |
| 32a | CLL | HR | C + P | NA | 0.03 |
| 33a | CLL | IR | None | NA | 0.03 |
| 1b | CLL | HR | C + P, Flu, 9AC | Yes | 0.19 |
| 2b | CLL | HR | C + P | NA | 0.24 |
| 3b | CLL | HR | Flu + Cy | No | 0.04 |
| 4b | CLL | HR | C + P, Fku, 2CDA | Yes | 0.21 |
| ID No. . | Diagnosis . | Modified Rai Stage . | Previous Treatment . | Fludarabine Refractory . | Flavopiridol LC50 (4 d) . |
|---|---|---|---|---|---|
| 1a | CLL | IR | None | NA | 0.18 |
| 2a | CLL | IR | None | NA | 0.20 |
| 3a | CLL | IR | None | NA | 0.09 |
| 5a | CLL | IR | None | NA | 0.16 |
| 6a | CLL | IR | None | NA | 0.20 |
| 7a | CLL | HR | C + P, Flu, CHOP | Yes | 0.20 |
| 8a | CLL | HR | C + P, 9AC | NA | 0.24 |
| 9a | CLL | HR | C + P, Flu, DHAP | Yes | 0.20 |
| 10a | CLL | HR | C + P, Cyt, Flu | Yes | 0.09 |
| 12a | CLL | IR | None | NA | 0.02 |
| 15a | CLL | IR | C + P | NA | 0.03 |
| 16a | CLL | IR | None | NA | 0.06 |
| 17a | CLL | HR | C + P, 9AC | NA | 0.18 |
| 23a | CLL | HR | None | NA | 0.077 |
| 24a | CLL | IR | None | NA | 0.11 |
| 26a | CLL | IR | None | NA | 0.21 |
| 27a | CLL | IR | None | NA | 0.09 |
| 28a | CLL | LR | None | NA | 0.22 |
| 29a | CLL | IR | None | NA | 0.08 |
| 30a | CLL | IR | None | NA | 0.08 |
| 31a | CLL | IR | None | NA | 0.07 |
| 32a | CLL | HR | C + P | NA | 0.03 |
| 33a | CLL | IR | None | NA | 0.03 |
| 1b | CLL | HR | C + P, Flu, 9AC | Yes | 0.19 |
| 2b | CLL | HR | C + P | NA | 0.24 |
| 3b | CLL | HR | Flu + Cy | No | 0.04 |
| 4b | CLL | HR | C + P, Fku, 2CDA | Yes | 0.21 |
Abbreviations: LR, low risk; IR, intermediate risk; HR, high risk; C, chlorambucil; P, prednisone; Flu, fludarabine; 2CDA, cladribine; Cy, cyclophosphamide; 9AC-9, aminocamptothecin; CHOP, cyclophosphamide, prednisone, vincristine, doxorubicin; DHAP, dexamethasone, cytarabine, cisplatin; NA, not applicable.